Multi-hit TP53 mutations significantly worsened survival in patients with myeloproliferative neoplasms (MPNs) and acute myeloid leukemia (AML), revealing critical prognostic insights.

Venetoclax showed “remarkable efficacy” in older patients, with an response rate of 91% in the octogenarian group—similar to what has been reported in younger cohorts. | Image credit: sovova - stock.adobe.com

Venetoclax Effective in Older Patients With CLL

By Jared Kaltwasser

June 20th 2025

Venetoclax demonstrated impressive efficacy in octogenarians with CLL, although treatment management posed some challenges.

Cleveland Clinic Main Campus | Image: Cleveland Clinic

Optimizing Advanced Cancer Therapies and Addressing Logistical, Financial Challenges

By Laura Joszt, MA

June 19th 2025

Coverage from IVBM Cleveland, held May 15, 2025.

Westin Forrestal Princeton | Image: Westin

Value-Based Care Calls for Putting Novel Therapies Closer to Patients

By Mary Caffrey

June 19th 2025

Coverage from IVBM Princeton, held May 8, 2025.

...

110 111 112 113 114

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions